Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
JAMA|August 10, 1994
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkR B Belshe, B S Graham, M C Keefer, et al.
The Journal of Infectious Diseases|December 1, 1993
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group NetworkR B Belshe, M L Clements, R Dolin, et al.
The Journal of Infectious Diseases|August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials NetworkB S Graham, R B Belshe, M L Clements, et al.
Annals of Internal Medicine|August 15, 1996
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation GroupB S Graham, M C Keefer, M J McElrath, et al.
AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
Pageof 3